Molecular Oncology Almanac
  • API
  • Approvals
  • Organizations
  • About
  • Contact

Revuforj (revumenib) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration.

Citation

Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. 4

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) t(KMT2A;v) Acute Lymphoid Leukemia Revumenib
Sensitivity (+) t(KMT2A;v) Acute Myeloid Leukemia Revumenib
Sensitivity (+) t(KMT2A;v) Burkitt Lymphoma Revumenib
Sensitivity (+) t(KMT2A;v) Acute Leukemias of Ambiguous Lineage Revumenib

Please review our privacy policy and terms before use.
API | Bluesky | Contact | GitHub

  • Dana-Farber logo
  • University of Limerick Digital Health Center logo
  • eHealthHub logo